https://orcid.org/0000-0002-3836-1827Figure 1. Immune response and pathogenesis of against SARS-CoV-2 (Figure is made with biorender).
Figure 2. Tocilizumab is an immunosuppressive drug, for the treatment of COVID-19 patients. It is a humanized monoclonal antibody against the IL-6 R and inhibits intracellular signaling in cells that express GP130 (Figure is made with biorender).
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
